Xcout IntelAnkyra Therapeutics, Inc.
Ankyra Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2019 and headquartered in Cambridge, Massachusetts. The enterprise specializes in developing proprietary anchored cytokine therapies designed to treat various cancers and immune diseases. Its platform technology localizes immune-stimulatory treatments within tumors to maximize therapeutic efficacy while minimizing systemic toxicity.
Subscribe to see Ankyra Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Ankyra Therapeutics, Inc. at a glance
Ankyra Therapeutics, Inc. is a biotechnology company headquartered in United States. Its most recent funding round raised $45M in August 2021. Xcout tracks 13 named people at Ankyra Therapeutics, Inc., including Howard L. Kaufman (President and Chief Executive Officer).
Ankyra Therapeutics, Inc. leadership
- Howard L. KaufmanPresident and Chief Executive Officer
- Stephen GorgolChief Financial Officer
- David MauroChief Medical Officer (Fractional)
- Gregory Zarbis-PapastoitsisChief Process and Manufacturing Officer
- Sailaja BattulaChief Scientific Officer
- Tillman GerngrossCo-Founder and Chairman of the Board
7 more named people on record for Ankyra Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Ankyra Therapeutics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $45M | — | |
| Series B | $45M | 13 named | |
| SEC Form D filing | $14.5M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Ankyra Therapeutics, Inc. competitors
A few of Ankyra Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Hiba Therapeutics is a biotechnology company headquartered in Cambridge, Massachusetts, United States, advancing a targeted approach through its TROIKA platform to activate tumor-resident T cells.
Actithera, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on delivering targeted radioligand cancer therapies.
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Kanyos Bio, Inc. is a biotechnology company located in Cambridge, Massachusetts, created as a subsidiary of Anokion SA to develop clinical candidates for immune tolerance.
Get Ankyra Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Ankyra Therapeutics, Inc.? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Ankyra Therapeutics, Inc. in Xcout Intel
- 13 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access